What is the management of reversed end diastolic flow?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Reversed End Diastolic Flow

For pregnancies with fetal growth restriction and reversed end-diastolic flow in the umbilical artery, delivery should be considered at 30-32 weeks of gestation as long as fetal surveillance remains reassuring. 1

Surveillance Protocol

  • Hospitalization is recommended when reversed end-diastolic flow (REDF) is detected in the umbilical artery 1
  • Heightened surveillance with cardiotocography (CTG) should be performed at least 1-2 times per day 1
  • Doppler assessment should be increased to 2-3 times per week when abnormal umbilical artery flow is detected 1, 2
  • Regular amniotic fluid volume assessment (twice weekly) is recommended for pregnancies with abnormal umbilical artery Doppler findings 2
  • Daily discussion with the consultant obstetrician about the clinical situation is essential 2

Antenatal Interventions

  • Antenatal corticosteroids should be administered if reversed end-diastolic flow is noted at <34 weeks in a pregnancy with suspected intrauterine growth restriction (IUGR) 1
    • This is a Level I evidence, level A recommendation 1
    • Corticosteroid administration may result in transient return of end-diastolic flow in about two-thirds of cases, attributed to altered tone of the placental vasculature 1
  • Magnesium sulfate for fetal neuroprotection should be administered if delivery is planned before 32 weeks gestation 1, 2

Timing of Delivery

  • Delivery at 30-32 weeks of gestation is recommended for pregnancies with fetal growth restriction and reversed end-diastolic flow 1
    • This is a Level 1B recommendation according to the Society for Maternal-Fetal Medicine 1
  • Earlier delivery may be indicated if there is:
    • Poor interval fetal growth
    • Deterioration of sonographic variables
    • Abnormal cardiotocography 2
  • Delaying delivery beyond the recommended gestational age increases the risk of adverse outcomes 2

Mode of Delivery

  • Cesarean delivery should be considered for pregnancies with fetal growth restriction complicated by reversed end-diastolic velocity, based on the entire clinical scenario 1
  • Studies show high rates of emergency cesarean section (80%) due to acute fetal distress in cases with REDF 3

Prognostic Implications

  • Reversed end-diastolic flow is associated with significantly worse outcomes compared to absent end-diastolic flow:
    • Higher perinatal mortality rates (up to 50-63%) 4, 3
    • Lower mean birth weights 4
    • Higher rates of admission to neonatal intensive care units 3
  • REDF represents an ominous finding that warrants urgent evaluation and intervention 5, 6
  • Placental examination often reveals significant infarcts (80% of cases) 3

Clinical Pitfalls to Avoid

  • Failing to differentiate between absent end-diastolic flow (delivery at 33-34 weeks) and reversed end-diastolic flow (delivery at 30-32 weeks) 1, 2
  • Managing these high-risk cases without daily consultant involvement 2
  • Delaying administration of corticosteroids, which should be given promptly when REDF is detected before 34 weeks 1
  • Expectant management beyond recommended delivery timing, which has not shown benefits in terms of long-term morbidity 7

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Absent End Diastolic Flow in Fetal Monitoring

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

The clinical significance of absent or reverse end-diastolic flow in the fetal aorta and umbilical artery.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology, 1991

Related Questions

What is the best course of action for a fetus with reversed end-diastolic flow on umbilical artery Doppler?
What is the most appropriate management for a patient at 33 weeks' gestation with a small for gestational age (SGA) fetus and reversed end-diastolic flow on umbilical artery Doppler?
What is the best course of action for a pregnant patient at 35 weeks of gestation with severe fetal growth restriction and absent end-diastolic flow on umbilical artery Doppler?
What is the best course of action for a primigravida (first-time pregnant woman) at 37 weeks gestation with severe hypertension, fetal growth restriction, and absent end diastolic flow?
What is the best course of action for a 30-something year old primigravida (first-time pregnant woman) at 37 weeks gestational age (GA) with severe hypertension, irritated on examination, and absent end diastolic flow?
What are the treatment options for managing type 1 and type 2 diabetes with medications such as insulin (e.g. glargine, aspart), metformin, sulfonylureas (e.g. glimepiride), DPP-4 inhibitors (e.g. sitagliptin), GLP-1 receptor agonists (e.g. liraglutide), and SGLT2 inhibitors (e.g. empagliflozin)?
What are the best practices for performing a Pap smear on a female with a Body Mass Index (BMI) greater than 50?
What is the mechanism of action of glucagon (Glucagon) in increasing blood glucose levels?
What is an unsuppressed menstrual cycle?
What are anti-inflammatory foods?
What is the recommended use and dosage of Semaglutide (Glucagon-like peptide-1 (GLP-1) receptor agonist) for patients with type 2 diabetes?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.